NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased TransMedics securities during the Class Period you may be entitled to compensation without payment of any ...

NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether TransMedics and certain o ...

Core Viewpoint - The TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements and unsafe practices during the specified class period [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Jewik v. TransMedics Group, Inc., and it allows investors who purchased TransMedics securities between February 28, 2023, and January 10, 2025, to seek appointment as lead plaintiff by April 15, 2025 [1][6]. - The lawsuit alleges that TransMedics engaged in unethical practices, including kickbacks and fraudulent overbilling, which contributed to a lack of safety oversight [3][5]. Group 2: Allegations and Impact - On February 21, 2024, U.S. Representative Paul Gosar accused TransMedics of misconduct, leading to a decline in the company's stock price following media coverage of the allegations [4]. - A report from Scorpion Capital on January 10, 2025, further accused TransMedics of overbilling and providing rejected organs to patients, resulting in another drop in stock price [5]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and has a strong track record in securing monetary relief for investors in securities fraud cases [7].

Core Viewpoint - A class action lawsuit has been filed against TransMedics Group, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its business practices and safety issues [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased between February 28, 2023, and January 10, 2025, during which investors are encouraged to participate before April 15, 2025 [2]. - The complaint alleges that TransMedics generated revenue through kickbacks, overbilling, and coercive tactics, while concealing safety issues and engaging in unsafe practices [4]. Group 2: Investor Representation - The class in this case has not yet been certified, meaning that potential class members are not currently represented by an attorney unless they take action [3]. - Investors who suffered losses are encouraged to contact the Schall Law Firm for a free discussion of their rights [3]. Group 3: Firm Background - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [5].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, alleging misleading statements and illegal business practices that negatively impacted the company's financial performance and stock price [1][3]. Group 1: Lawsuit Details - The lawsuit was filed by Scott+Scott Attorneys at Law LLP in the U.S. District Court for the District of Massachusetts, asserting claims under the Securities Exchange Act of 1934 [1]. - The class action includes all individuals who purchased TransMedics securities between February 28, 2023, and January 10, 2025, and were harmed as a result [1][6]. Group 2: Allegations Against TransMedics - Defendants are accused of failing to disclose reliance on illegal and coercive business practices, including kickbacks, billing fraud, and overcharging patients, which led to a decline in customer usage and increased regulatory scrutiny [3]. - The company experienced its first sequential revenue decline since Q3 2021, with a significant drop in stock price following the announcement of its Q3 2024 financial results [4]. Group 3: Impact on Stock Price - Following the release of a report by Scorpion Capital on January 10, 2025, which accused TransMedics of overbilling hospitals, the stock price fell by $3.74 per share, or 5.15%, closing at $68.81 [5]. - The stock continued to decline, falling an additional $4.76 per share, or 6.9%, to close at $64.05 on January 13, 2025 [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In TransMedics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in TransMedics between February 23, 2023 and January 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 13, 2 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased TransMedics Group, Inc. securities between February 28, 2023, and January 10, 2025, of the April 15, 2025, deadline to become lead plaintiffs in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased TransMedics securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6]. - The lawsuit alleges that TransMedics made materially false and misleading statements regarding its business practices, including the use of kickbacks and fraudulent overbilling, which led to regulatory scrutiny and investor damages [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for allegedly misleading investors regarding business practices and safety issues during the Class Period from February 28, 2023, to January 10, 2025 [1][3]. Company Overview - TransMedics Group, Inc. is a medical technology company based in Andover, Massachusetts, specializing in transplant services, including its Organ Care System (OCS), which is a portable organ preservation system [2]. Allegations - The lawsuit claims that TransMedics and its executives misled investors by failing to disclose the use of kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [3]. - Additionally, it is alleged that the company concealed safety issues and a lack of safety oversight within the organization [3]. Impact on Stock Price - Following the revelation of these issues, TransMedics' stock price fell by $2.18 (2.5%) to $84.81 on February 22, 2024, after U.S. Rep. Paul Gosar's accusations [4]. - On January 10, 2025, after a report from Scorpion Capital, the stock dropped by $3.74 (5%) to $68.81, and further declined by $4.76 (6.9%) to close at $64.05 on January 13, 2025 [5].

SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, inclusive (the “Class Period”), have until this Tuesday, April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit. Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit c ...

NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visitin: https://www.bfalaw.com/cases-investigations/transmedics-group-inc Investors have until April 15, 2025, to ask the Court to be ...